It has been said that technology used in the lab does not directly transfer to what is done in healthcare. Research on the use of Artificial Intelligence (AI) in the diagnosis of Diabetic Retinopathy (DR) has seen tremendous growth over the last couple of years but it is also true not much of that knowledge has been transferred into practice to benefit patients in need. One reason is that it’s a new frontier with untested technologies and one that is evolving too fast. Also, the Real Healthcare situation can be very complicated presenting itself with numerous challenges starting with strict regulations to variability in populations. A solution that is implementable needs to address all these concerns including ethics, standards, and any security concerns. It is also important to note that, the current state of AI is specialized to only narrow applications and may not scale when presented with problems of varied nature. A case in point is a patient having DR may be suffering from other ailments such as Glaucoma or cataracts. DR has been a leading cause of blindness for millions of people worldwide, hard to detect when it’s treatable and therefore early eye screening is the solution. In this Capstone project, we seek to integrate Artificial Intelligence with other technologies to deliver a low-cost diagnosis to Diabetic Retinopathy at the same time trying to overcome previous impediments to the implementation of mass eye screening.
Professional Studies (MS)
Department, Program, or Center
Graduate Programs & Research (Dubai)
Mwasikira, David Mwanguo, "Development of a Low-Cost Eye Screening Tool for Early Detection of Diabetic Retinopathy using Deep Neural Network" (2021). Thesis. Rochester Institute of Technology. Accessed from